特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
670559

世界の呼吸器疾患治療薬市場の分析と動向

Global Respiratory Drug Market Research and Forecast 2018-2023

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
世界の呼吸器疾患治療薬市場の分析と動向
出版日: 2018年07月13日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の呼吸器疾患治療薬市場を調査し、市場の概要、治療薬・タイプ・投与経路・エンドユーザー・地域別の市場規模の推移と予測、市場動向、成長要因・阻害要因ならびに市場機会の分析、規制環境、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 レポート概要

  • 調査手法
  • 市場の内訳
    • セグメント別
    • 地域別
    • ステークホルダー別

第2章 市場概要と考察

  • 市場の定義
  • 市場考察・市場動向
    • 主な調査結果
    • 提言
    • 総論
  • パイプライン分析
  • 主な呼吸器疾患治療薬の分析
  • 呼吸器疾患
    • 喘息
    • 慢性閉塞性肺疾患(COPD)
    • 嚢胞性線維症
    • 慢性気管支炎
    • 肺気腫
    • アレルギー性鼻炎
    • その他
  • 規制環境
    • 米国
    • 中国
    • インド
    • 日本

第3章 市場影響要因

  • 成長要因
  • 阻害要因
  • 市場機会

第4章 市場区分

  • 世界の呼吸器疾患治療薬市場:治療薬別
    • アドエア
    • シムビコート
    • スピリーバ
    • ゾレア
    • ベントリン
    • パルミコート
    • オルカンビ
    • レルベア/ブレオ/エリプタ
    • シングレア
    • エスブリット
    • カリデコ
    • エピペン
    • オフェブ
    • その他
  • 世界の呼吸器疾患治療薬市場:タイプ別
    • 坑凝固剤
    • 坑ヒスタミン薬
    • ベータ2阻害薬
    • 坑喘息薬
    • 副腎皮質ホルモン
    • ロイコトリエン阻害薬
    • マスト細胞安定化薬
    • ホスホジェステラーゼ4阻害薬
    • 気管支拡張薬
    • 充血除去薬
    • 去痰薬
    • その他
  • 世界の呼吸器疾患治療薬市場:投与経路別
    • 経口投与薬
    • 注射剤
    • 吸入薬
  • 世界の呼吸器疾患治療薬市場:エンドユーザー別
    • 病院
    • 在宅ケア
    • その他

第5章 競合情勢

  • 市場シェアの分析
  • 主要企業の分析

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • インド
    • 中国
    • 日本
  • その他の地域

第7章 企業プロファイル

  • AIR LIQUIDE
  • ARADIGM CORPORATION
  • ASTRAZENECA PLC
  • BAXTER INTERNATIONAL INC.
  • BEXIMCO PHARMACEUTICALS LTD.
  • BOEHRINGER INGELHEIM GMBH
  • COMPUMEDICS LTD.
  • COVIDIEN PLC
  • DRAGER MEDICAL GMBH
  • F. HOFFMANN-LA ROCHE LTD
  • FISHER AND PAYKEL HEALTHCARE CORP. LTD
  • GE HEALTHCARE LIMITED
  • GENENTECH, INC.
  • GLAXOSMITHKLINE PLC
  • GRIFOLS, S.A.
  • HAMILTON MEDICAL AG
  • INVACARE CORPORATION
  • KONINKLIJKE PHILIPS N.V.
  • MERCK AND CO.
  • METHAPHARM, INC.
  • MYLAN N.V.
  • NABRIVA THERAPEUTICS PLC
  • NEPHRON PHARMACEUTICALS CORPORATION
  • NOVABIOTICS LTD.
  • NOVALUNG GMBH
  • NOVARTIS INTERNATIONAL AG
  • オムロン
  • OPKO HEALTH, INC.
  • OREXO AB
  • 大塚製薬
  • PALOBIOFARMA S.L.
  • PFIZER INC.
  • SAVARA, INC.
  • 大日本住友製薬
  • SUNOVION PHARMACEUTICALS INC.
  • 武田薬品
  • TEVA PHARMACEUTICALS INC.
  • UNITED THERAPEUTICS CORPORATION
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • VERONA PHARMA PLC
  • VERTEX PHARMACEUTICALS INC.

図表一覧

図表

List of Tables

  • TABLE # 1 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL ADVAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL SYMBICORT TURBUHALER MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL SPIRIVA MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL XOLAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL VENTOLIN MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL PULMICORT MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL ORKAMBI MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL RELVAR/BREO ELLIPTA MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL SINGULAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL ESBRIET MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL KALYDECO MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL EPIPEN MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL OFEV MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 16 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 17 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
  • TABLE # 18 GLOBAL ORAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 19 GLOBAL INJECTABLE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 20 GLOBAL INHALABLE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 21 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
  • TABLE # 22 GLOBAL ANTICHOLINERGICS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 23 GLOBAL ANTIHISTAMINES MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 24 GLOBAL BETA2 AGONISTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 25 GLOBAL ANTIASTHMATICS COMBINATIONS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 26 GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 27 GLOBAL LEUKOTRIENE INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 28 GLOBAL MAST CELL STABILIZERS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 29 GLOBAL PDE4 INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 30 GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 31 GLOBAL DECOGESTANTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 32 GLOBAL EXPECTORANTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 33 GLOBAL OTHER RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 34 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
  • TABLE # 35 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY APPLICATIONS 2017-2023 ($ MILLION)
  • TABLE # 36 GLOBAL HOME CARE MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 37 GLOBAL OTHER END USERS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
  • TABLE # 38 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
  • TABLE # 39 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
  • TABLE # 40 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUGS CLASS 2017-2023 ($ MILLION)
  • TABLE # 41 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
  • TABLE # 42 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
  • TABLE # 43 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
  • TABLE # 44 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
  • TABLE # 45 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUGS CLASS 2017-2023 ($ MILLION)
  • TABLE # 46 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
  • TABLE # 47 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
  • TABLE # 48 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
  • TABLE # 49 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
  • TABLE # 50 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
  • TABLE # 51 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
  • TABLE # 52 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
  • TABLE # 53 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
  • TABLE # 54 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
  • TABLE # 55 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
  • TABLE # 56 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY DRUG 2017 VS 2023 (IN %)
  • FIGURE # 2 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION 2017 VS 2023 (IN %)
  • FIGURE # 3 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY DRUGS CLASS 2017 VS 2023 (IN %)
  • FIGURE # 4 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY END USERS 2017 VS 2023 (IN %)
  • FIGURE # 5 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY GEOGRAPHY 2017 VS 2023 (IN %)
  • FIGURE # 6 NORTH AMERICA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 7 US RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 8 CANADA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 9 EUROPEAN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 10 UK RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 11 FRANCE RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 12 GERMANY RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 13 ITALY RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 14 SPAIN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 15 ROE RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 16 ASIA PACIFIC RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 17 INDIA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 18 CHINA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 19 JAPAN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 20 ROAPAC RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 21 REST OF THE WORLD RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
目次
Product Code: OMR2018324

The global respiratory drug market is expected to grow significantly during forecast period. Several respiratory drugs are given by inhalation, although enteral, parenteral, transdermal, or topical routes of administration may be used for some respiratory drugs. Inhalation route of administration has various advantages over systemic administration such as a smaller dose can be used, adverse effects are often reduced, the drug is delivered quickly to lung tissue or the bloodstream, administration is painless, and delivery is usually safe and convenient. The respiratory drugs are used to treat several respiratory diseases such as asthma, COPD (chronic obstructive pulmonary disease), cystic fibrosis, chronic bronchitis, emphysema and allergic rhinitis.

Major factors contributing to the growth of the global respiratory drug market include increasing prevalence of chronic respiratory diseases such as asthma and COPD. This is mainly owing to increasing smoking and pollution across the globe. Growing cases of respiratory diseases in new born and children and changing lifestyle and rise in obesity are fueling the market growth. Moreover, innovations and development of new drugs such as Dupilumab for severe asthma is significantly contributing in the market growth. However, reimbursements and strict government regulations and limited awareness and availability are some of the factors hindering the growth of the market. Lack of awareness among population of emerging countries is hampering the growth of the global respiratory drug market. However, robust pipeline products and emerging markets is expected to fuel the market growth in the near future.

The global respiratory drug market can be segmented on the basis of drug, drug class, route of administration, and end user. The market by drug class is segmented on the basis of currently available medication options for the treatment of symptoms of respiratory disorders reduce the symptoms for disease control. Generally, six classes of drug and nasal saline are used to treat asthma, oral and topical H1-antihistamines, mast cell stabilizers (i.e., cromones), decongestants, anticholinergic agents, and leukotriene inhibitors. Medications used for asthma are characteristically administered orally or intranasally. The intranasal route allows higher concentrations of the drug to be delivered, thus minimizing systemic side effects.

The global respiratory drug market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global respiratory drug market, followed by Europe. This is mainly owing to rising prevalence of chronic respiratory diseases in the region, especially in the US. The increasing research and development in respiratory drug development is expected to further drive the growth of the respiratory drug market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are increasing investment by pharmaceuticals companies. For instance, in India, India's Cipla expects to double respiratory drug sales by 2020. Further, Indian companies such as Dr Reddy's Laboratories, Lupin and Cipla are expected to build expertise in the respiratory drug market.

Some of the key players operating in the global respiratory drug market are GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, AstraZeneca PLC, Merck & Co., Inc., Novartis International AG, Omron Corporation, and Sunovion Pharmaceuticals Inc. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance,

Research Methodology

The market study of respiratory drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Authentic public databases such as American Academy of Family Physicians (aafp.org), org, and effectivenessevaluation.org.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalogue
  • Supplier Websites such as Alibaba, amazon for pricing analysis

The report is intended for hospitals, private companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation:

  • Global respiratory drug market is segmented on the basis of regional outlook and following segments:
  • Global Respiratory drug market Research and Analysis, By Drug
  • Global Respiratory drug market Research and Analysis, By Drug Class
  • Global Respiratory drug market Research and Analysis, By Route of Administration
  • Global Respiratory drug market Research and Analysis, By End User
  • Global Respiratory drug market Research and Analysis, By Region

The Report covers:

  • Comprehensive research methodology of global respiratory drug market
  • This report also includes detailed and extensive market overview with key analyst insights
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
  • Analysis of regional regulations and other government policies impacting the global respiratory drug market
  • Insights about market determinants which are stimulating the global respiratory drug market
  • Detailed and extensive market segments with regional distribution of forecasted revenues
  • Extensive profiles and recent developments of market players

Table of Contents

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. MARKET DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. PIPELINE ANALYSIS
  • 2.4. TOP RESPIRATORY DRUGS ANALYSIS
  • 2.5. RESPIRATORY DISEASES
    • 2.5.1. ASTHMA
    • 2.5.2. COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
    • 2.5.3. CYSTIC FIBROSIS
    • 2.5.4. CHRONIC BRONCHITIS
    • 2.5.5. EMPHYSEMA
    • 2.5.6. ALLERGIC RHINITIS
    • 2.5.7. OTHER
  • 2.6. REGULATIONS
    • 2.6.1. UNITED STATE
    • 2.6.2. CHINA
    • 2.6.3. INDIA
    • 2.6.4. JAPAN

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. HIGH PREVALENCE OF CHRONIC RESPIRATORY DISEASES SUCH AS ASTHMA AND COPD
    • 3.1.2. GROWING CASES OF RESPIRATORY DISEASES IN NEW BORN AND CHILDREN
    • 3.1.3. CHANGING LIFESTYLE AND RISE IN OBESITY
    • 3.1.4. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
  • 3.2. RESTRAINTS
    • 3.2.1. REIMBURSEMENTS AND STRICT GOVERNMENT REGULATIONS
    • 3.2.2. LIMITED AWARENESS AND AVAILABILITY
  • 3.3. OPPORTUNITIES
    • 3.3.1. ROBUST PIPELINE PRODUCTS
    • 3.3.2. EMERGING MARKETS

4. MARKET SEGMENTATION

  • 4.1. RESPIRATORY DRUGS MARKET BY DRUG
    • 4.1.1. ADVAIR
    • 4.1.2. SYMBICORT TURBUHALER
    • 4.1.3. SPIRIVA
    • 4.1.4. XOLAIR
    • 4.1.5. VENTOLIN
    • 4.1.6. PULMICORT
    • 4.1.7. ORKAMBI
    • 4.1.8. RELVAR/BREO ELLIPTA
    • 4.1.9. SINGULAIR
    • 4.1.10. ESBRIET
    • 4.1.11. KALYDECO
    • 4.1.12. EPIPEN
    • 4.1.13. OFEV
    • 4.1.14. OTHER
  • 4.2. RESPIRATORY DRUGS MARKET BY DRUG CLASS
    • 4.2.1. ANTICHOLINERGICS
    • 4.2.2. ANTIHISTAMINES
    • 4.2.3. BETA2 AGONISTS
    • 4.2.4. ANTIASTHMATIC COMBINATIONS
    • 4.2.5. CORTICOSTEROIDS
    • 4.2.6. LEUKOTRIENE INHIBITORS
    • 4.2.7. MAST CELL STABILIZERS
    • 4.2.8. PHOSPHODIESTERASE 4 (PDE4) INHIBITORS
    • 4.2.9. BRONCHODILATORS
    • 4.2.10. DECONGESTANTS
    • 4.2.11. EXPECTORANTS
    • 4.2.12. OTHER RESPIRATORY DRUGS
  • 4.3. RESPIRATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
    • 4.3.1. ORAL RESPIRATORY DRUGS
    • 4.3.2. INJECTABLE RESPIRATORY DRUGS
    • 4.3.3. INHALABLE RESPIRATORY DRUGS
  • 4.4. RESPIRATORY DRUGS MARKET BY END USERS
    • 4.4.1. HOSPITALS
    • 4.4.2. HOME CARE
    • 4.4.3. OTHER END USERS

5. COMPETITIVE LANDSCAPE

  • 5.1. MARKET SHARE ANALYSIS
  • 5.2. KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
    • 6.1.3. REST OF NORTH AMERICA
  • 6.2. EUROPE
    • 6.2.1. UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. SPAIN
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD

7. COMPANY PROFILES

  • 7.1. AIR LIQUIDE
  • 7.2. ARADIGM CORPORATION
  • 7.3. ASTRAZENECA PLC
  • 7.4. BAXTER INTERNATIONAL INC.
  • 7.5. BEXIMCO PHARMACEUTICALS LTD.
  • 7.6. BOEHRINGER INGELHEIM GMBH
  • 7.7. COMPUMEDICS LTD.
  • 7.8. COVIDIEN PLC
  • 7.9. DRAGER MEDICAL GMBH
  • 7.10. F. HOFFMANN-LA ROCHE LTD
  • 7.11. FISHER AND PAYKEL HEALTHCARE CORP. LTD
  • 7.12. GE HEALTHCARE LIMITED
  • 7.13. GENENTECH, INC.
  • 7.14. GLAXOSMITHKLINE PLC
  • 7.15. GRIFOLS, S.A.
  • 7.16. HAMILTON MEDICAL AG
  • 7.17. INVACARE CORPORATION
  • 7.18. KONINKLIJKE PHILIPS N.V.
  • 7.19. MERCK AND CO.
  • 7.20. METHAPHARM, INC.
  • 7.21. MYLAN N.V.
  • 7.22. NABRIVA THERAPEUTICS PLC
  • 7.23. NEPHRON PHARMACEUTICALS CORPORATION
  • 7.24. NOVABIOTICS LTD.
  • 7.25. NOVALUNG GMBH
  • 7.26. NOVARTIS INTERNATIONAL AG
  • 7.27. OMRON CORPORATION
  • 7.28. OPKO HEALTH, INC.
  • 7.29. OREXO AB
  • 7.30. OTSUKA PHARMACEUTICALS INC.
  • 7.31. PALOBIOFARMA S.L.
  • 7.32. PFIZER INC.
  • 7.33. SAVARA, INC.
  • 7.34. SUMITOMO DAINIPPON PHARMA CO., LTD.
  • 7.35. SUNOVION PHARMACEUTICALS INC.
  • 7.36. TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 7.37. TEVA PHARMACEUTICALS INC.
  • 7.38. UNITED THERAPEUTICS CORPORATION
  • 7.39. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • 7.40. VERONA PHARMA PLC
  • 7.41. VERTEX PHARMACEUTICALS INC.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.